Microarray determination of Bcl-2 family protein inhibition sensitivity in breast cancer cells

被引:7
作者
Hudson, Sandra G. [1 ]
Halleran, Devin R. [2 ]
Nevaidine, Barbara [1 ]
Shapiro, Anna [1 ]
Hutchison, Robert E. [2 ]
Hahn, Peter J. [1 ]
机构
[1] SUNY Upstate Med Univ, Dept Radiat Oncol, Syracuse, NY 13210 USA
[2] SUNY Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA
关键词
personalized medicine; obatoclax; Bcl-2 (B-cell leukemia lymphoma-2); apoptosis; radiation; breast cancer; PHASE-I; OBATOCLAX MESYLATE; BH3-ONLY PROTEINS; INDUCED APOPTOSIS; EXPRESSION; DOXORUBICIN; ANTAGONIST; RESISTANCE; GX15-070; THERAPY;
D O I
10.1177/1535370212474582
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
This study tests the hypothesis that reverse transcription polymerase chain reaction (RT-PCR) microarrays can be used to predict the relative sensitivity to induction of apoptosis in breast cancer cells exposed to inhibitors of antiapoptotic Bcl-2 family proteins. Four cell lines, MDA-MB-231 (MDA-231) and MDA-MB-468 (MDA-468), BT-20 and T47-D were screened for relative expression of Bcl-2 family members A1, Mcl-1, Bcl-2, Bcl-xL and Bcl-w mRNA by RT-PCR microarrays and Western analysis. The four cell lines were treated with 1 mu mol/L obatoclax (GX15-070) and/or 2 Gy radiation (RT) and monitored for apoptosis after 48 h. Cell lines showing the highest total fold-increase of Bcl-2 family member mRNA, MDA-231 and MDA-468, also showed the highest levels of apoptosis induction (approximately 70% with obatoclax alone and 82% with obatoclax plus RT). Cell lines with little or no increase in Bcl-2 family mRNA (BT-20 and T47-D) showed less apoptosis (30% following treatment with obatoclax and 42% with obatoclax plus RT). RT-PCR arrays can predict the relative apoptosis response of breast cancer cells to the pan Bcl-2 inhibitor obatoclax alone or when combined with radiation.
引用
收藏
页码:248 / 256
页数:9
相关论文
共 54 条
[1]   The Bcl-2 apoptotic switch in cancer development and therapy [J].
Adams, J. M. ;
Cory, S. .
ONCOGENE, 2007, 26 (09) :1324-1337
[2]   An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737 [J].
Al-Harbi, Sayer ;
Hill, Brian T. ;
Mazumder, Suparna ;
Singh, Kamini ;
DeVecchio, Jennifer ;
Choudhary, Gaurav ;
Rybicki, Lisa A. ;
Kalaycio, Matt ;
Maciejewski, Jaroslaw P. ;
Houghton, Janet A. ;
Almasan, Alexandru .
BLOOD, 2011, 118 (13) :3579-3590
[3]  
Alsabeh R, 1996, MODERN PATHOL, V9, P439
[4]   Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor [J].
An, J. ;
Chervin, A. S. ;
Nie, A. ;
Ducoff, H. S. ;
Huang, Z. .
ONCOGENE, 2007, 26 (05) :652-661
[5]   Multiple Drug Resistance Mechanisms in Cancer [J].
Baguley, Bruce C. .
MOLECULAR BIOTECHNOLOGY, 2010, 46 (03) :308-316
[6]  
Bayes M, 2007, Methods Find Exp Clin Pharmacol, V29, P427
[7]   Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small cell lung cancer [J].
Borner, MM ;
Brousset, P ;
Pfanner-Meyer, B ;
Bacchi, M ;
Vonlanthen, S ;
Hotz, MA ;
Altermatt, HJ ;
Schlaifer, D ;
Reed, JC ;
Betticher, DC .
BRITISH JOURNAL OF CANCER, 1999, 79 (5-6) :952-958
[8]  
BRUCKMAN JE, 1979, CANCER-AM CANCER SOC, V43, P985, DOI 10.1002/1097-0142(197903)43:3<985::AID-CNCR2820430330>3.0.CO
[9]  
2-1
[10]   Novel anticancer drug discovery [J].
Buolamwini, JK .
CURRENT OPINION IN CHEMICAL BIOLOGY, 1999, 3 (04) :500-509